Rhenman & Partners Asset Management’s BioNTech BNTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,870	Closed	-$1.99M	–	89
2025 Q4	$1.99M	Sell	20,870 -15,000	-42%	-$1.51M	0.19%	87
2025 Q3	$3.54M	Hold	35,870	–	–	0.39%	68
2025 Q2	$3.82M	Buy	35,870 +120	+0.3%	+$12.1K	0.48%	59
2025 Q1	$3.26M	Sell	35,750 -17,000	-32%	-$1.9M	0.37%	57
2024 Q4	$6.01M	Buy	52,750 +1,750	+3%	+$200K	0.62%	50
2024 Q3	$6.06M	Buy	+51,000	New	+$4.69M	0.49%	61
2023 Q4	–	Sell	-53,000	Closed	-$5.76M	–	88
2023 Q3	$5.76M	Sell	53,000 -17,000	-24%	-$1.88M	0.62%	47
2023 Q2	$7.56M	Sell	70,000 -22,000	-24%	-$2.47M	0.8%	42
2023 Q1	$11.3M	Sell	92,000 -17,000	-16%	-$2.33M	1.24%	30
2022 Q4	$16.4M	Buy	109,000 +10,000	+10%	+$1.54M	1.71%	23
2022 Q3	$13.6M	Buy	99,000 +9,000	+10%	+$1.38M	1.43%	27
2022 Q2	$13.4M	Buy	90,000 +5,000	+6%	+$764K	1.52%	26
2022 Q1	$14.5M	Buy	+85,000	New	+$14.3M	1.43%	29

Other funds holding BNTX

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rhenman & Partners Asset Management's BNTX Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of BioNTech (BNTX) in Q1 2026, closing a stake of 20,870 shares — an estimated $1.99M sold.

Rhenman & Partners Asset Management first reported a position in BNTX in Q1 2022 and held it in 13 quarters. The position peaked at $16.4M in Q4 2022. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

Rhenman & Partners Asset Management reported no remaining BioNTech position as of Q1 2026 after selling out during the quarter.
Rhenman & Partners Asset Management sold 20,870 BioNTech shares in Q1 2026, an estimated $1.99M.
Rhenman & Partners Asset Management first reported a position in BioNTech in Q1 2022 and held it in 13 quarters.
Rhenman & Partners Asset Management's BioNTech position peaked at $16.4M in Q4 2022.
272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.